Caroline E Beauregard
Overview
Explore the profile of Caroline E Beauregard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beug S, Cheung H, Sanda T, St-Jean M, Beauregard C, Mamady H, et al.
Sci Signal
. 2019 Jan;
12(566).
PMID: 30696705
The controlled production and downstream signaling of the inflammatory cytokine tumor necrosis factor-α (TNF-α) are important for immunity and its anticancer effects. Although chronic stimulation with TNF-α is detrimental to...
2.
Beug S, Beauregard C, Healy C, Sanda T, St-Jean M, Chabot J, et al.
Nat Commun
. 2018 Jul;
9:16231.
PMID: 30019697
This corrects the article DOI: 10.1038/ncomms14278.
3.
Beug S, Beauregard C, Healy C, Sanda T, St-Jean M, Chabot J, et al.
Nat Commun
. 2017 Feb;
8.
PMID: 28198370
Small-molecule inhibitor of apoptosis (IAP) antagonists, called Smac mimetic compounds (SMCs), sensitize tumours to TNF-α-induced killing while simultaneously blocking TNF-α growth-promoting activities. SMCs also regulate several immunomodulatory properties within immune...
4.
Beug S, Tang V, LaCasse E, Cheung H, Beauregard C, Brun J, et al.
Nat Biotechnol
. 2014 Jan;
32(2):182-90.
PMID: 24463573
Smac mimetic compounds (SMC), a class of drugs that sensitize cells to apoptosis by counteracting the activity of inhibitor of apoptosis (IAP) proteins, have proven safe in phase 1 clinical...